Entering text into the input field will update the search result below

Altimmune: Changing Focus To Pemvidutide In 2022

Jan. 03, 2022 1:58 AM ETAltimmune, Inc. (ALT) Stock3 Comments


  • Altimmune is changing its focus from infectious diseases towards metabolic and liver diseases. The company is leaning on Pemvidutide for obesity, NAFLD, and NASH.
  • So far, the dual GLP-1/glucagon receptor agonist has produced impressive results in addressing metabolic dysfunction, which evolves into chronic diseases and comorbidity.
  • If approved, Pemvidutide could be one of the first drugs on the market for NASH and potentially best-in-class in its target indications. Altimmune could have a blockbuster drug.
  • Altimmune has Pemvidutide moving ahead for all three indications. The Phase Ib NAFLD data is expected in the first half of next year.
  • I discuss my plan for managing my ALT around Pemvidutide’s development.

Human Internal Digestive Organ Liver Anatomy

magicmine/iStock via Getty Images

The last year has been a very productive time for Altimmune (NASDAQ:ALT) as the company’s clinical efforts have revealed Pemvidutide’s potential to be a metabolic and liver disease powerhouse therapeutic. Altimmune’s dual GLP-1/glucagon receptor agonist

This article was written by

Biologics profile picture

Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative companies developing breakthrough therapies and/or pharmaceuticals with catalysts for potential acquisitions.

He is the leader of the investing group Compounding Healthcare. Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ALT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (3)

shake shake money tree profile picture
semaglutide (Wegovy) is approved by FDA last year.
How does this stack up against Rybelsus?
Nice piece of info. Who's the competitor?
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About ALT

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ALT

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.